GT Biopharma (OXIS) Announces Enrollment of Fourth Patient in FDA Phase 2 Trial of Cancer Drug OXS-1550 August 2, 2017
Oxis Releases Additional Details about Acquisition of Georgetown Translational Pharmaceuticals, Oxis to Change Name to "GT Biopharma, Inc." July 25, 2017
Oxis Agrees to Acquire Georgetown Translational Pharmaceuticals, Appoints New Chief Executive Officer and Chief Medical Officer June 26, 2017
Oxis Enters into a Co-Development Partnership Agreement with Altor Bioscience for Novel TriKE Therapeutic June 13, 2017
Oxis International Inc. Announces Treatment of First Patient in FDA Phase 2 Trial of Cancer Drug OXS-1550 April 18, 2017
Oxis International Inc. Announces Approval of FDA Phase 2 Trial with Its Bispecific Antibody OXS-1550 April 4, 2017
Oxis International Enters into a Sponsored Research Agreement with the University of Minnesota March 23, 2017
OXIS Biotech Scientific Advisory Board Member to Address Cancer Immunotherapy Conference in China March 21, 2017
Oxis Biotech Announces U.S. Patent and Trademark Office Notification of Patent Issuance for Oxis-4235 as Treatment for Multiple Myeloma February 21, 2017
